PFE - Pfizer Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
41.10
+0.39 (+0.96%)
As of 1:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close40.71
Open40.80
Bid41.090 x 3200
Ask41.100 x 1000
Day's Range40.65 - 41.12
52 Week Range32.32 - 41.64
Volume9,911,478
Avg. Volume20,108,429
Market Cap240.417B
Beta0.96
PE Ratio (TTM)10.98
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.33%)
Ex-Dividend Date2018-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity
    Bloomberg1 hour ago

    A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity

    People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.

  • TheStreet.com1 hour ago

    Buy Stocks That Are Down, Not Up, Here

    Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.

  • 3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
    Motley Fool4 hours ago

    3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

    An FDA approval is a big step, but some big challenges remain.

  • Novo Nordisk’s Biopharmaceuticals Segment: An Update
    Market Realist6 hours ago

    Novo Nordisk’s Biopharmaceuticals Segment: An Update

    Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.

  • What's Next for Spark Therapeutics
    Motley Fool7 hours ago

    What's Next for Spark Therapeutics

    This gene therapy biotech has its sights set on a second commercial-stage opportunity

  • Pfizer Expected to Report Robust EPS Rise in Fiscal 2018
    Market Realistyesterday

    Pfizer Expected to Report Robust EPS Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.

  • How IBM’s Global Business Services Unit Is Doing
    Market Realistyesterday

    How IBM’s Global Business Services Unit Is Doing

    IBM’s (IBM) Global Business Services unit, which represents ~21% of its total business, comprises its consulting, global business services, and application management offerings. In the last five quarters, the segment has grown 0.6% compounded annually, driven by improvement in its consulting business.

  • Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
    Market Realistyesterday

    Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

  • How GlaxoSmithKline’s Segments Have Performed
    Market Realist2 days ago

    How GlaxoSmithKline’s Segments Have Performed

    As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...

  • How GlaxoSmithKline’s Valuation Compares with Peers’
    Market Realist2 days ago

    How GlaxoSmithKline’s Valuation Compares with Peers’

    Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017. 

  • 3 Beaten-Down Biotech Stocks: Can They Recover?
    Motley Fool3 days ago

    3 Beaten-Down Biotech Stocks: Can They Recover?

    Is there a light at the end of the tunnel?

  • GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript

    GLYC earnings call for the period ending June 30, 2018.

  • InvestorPlace5 days ago

    GlycoMimetics Stock Has Substantial Upside

    GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.

  • Barrons.com5 days ago

    Pharma Stocks Are Starting to Look More Attractive

    Healthcare has been a strong performer lately, and pharma stocks are garnering more interest from investors. Where we were: Worries about drug prices had been one knock against the pharma sector. Where we're headed: Investors are getting more interested in the stocks, on hopes that policy changes won't be a headwind.

  • InvestorPlace5 days ago

    You Better Be Careful with Merck Stock, Especially at These Highs

    Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.

  • In $270M Peninsula vaccine company buyout, small players look to be big shots
    American City Business Journals5 days ago

    In $270M Peninsula vaccine company buyout, small players look to be big shots

    A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.

  • Motley Fool6 days ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • ICU Medical, Inc. (ICUI) Q2 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    ICU Medical, Inc. (ICUI) Q2 2018 Earnings Conference Call Transcript

    ICUI earnings call for the period ending June 30, 2018.

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist6 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • Cabozantinib Expected to Be Exelixis’s Long-Term Growth Driver
    Market Realist6 days ago

    Cabozantinib Expected to Be Exelixis’s Long-Term Growth Driver

    In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.

  • Why Sangamo Therapeutics, Inc. Stock Is Popping Today
    Motley Fool6 days ago

    Why Sangamo Therapeutics, Inc. Stock Is Popping Today

    The clinical-stage biotech reported encouraging news for its gene therapy targeting treatment of hemophilia A.

  • Analysts’ Recommendations for Pfizer on August 6
    Market Realist6 days ago

    Analysts’ Recommendations for Pfizer on August 6

    Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.

  • Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
    Zacks6 days ago

    Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

    Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Examining Pfizer’s Valuation as of August 6
    Market Realist6 days ago

    Examining Pfizer’s Valuation as of August 6

    Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.